title: Inhibiting MEK in MAPK pathway-activated myeloma.
authors.affiliation: Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: C J
authors.initials: CJ
authors.lastname: Heuck
authors.affiliation: Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Jethava
authors.affiliation: Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: R
authors.initials: R
authors.lastname: Khan
authors.affiliation: Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: F
authors.initials: F
authors.lastname: van Rhee
authors.affiliation: Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: M
authors.initials: M
authors.lastname: Zangari
authors.affiliation: Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: S
authors.initials: S
authors.lastname: Chavan
authors.affiliation: Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: K
authors.initials: K
authors.lastname: Robbins
authors.affiliation: Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: S E
authors.initials: SE
authors.lastname: Miller
authors.affiliation: Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: A
authors.initials: A
authors.lastname: Matin
authors.affiliation: Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: M
authors.initials: M
authors.lastname: Mohan
authors.affiliation: Foundation Medicine, Inc., Cambridge, MA, USA.
authors.forename: S M
authors.initials: SM
authors.lastname: Ali
authors.affiliation: Foundation Medicine, Inc., Cambridge, MA, USA.
authors.forename: P J
authors.initials: PJ
authors.lastname: Stephens
authors.affiliation: Foundation Medicine, Inc., Cambridge, MA, USA.|Department of Pathology, Albany Medical College, Albany, NY, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Ross
authors.affiliation: Foundation Medicine, Inc., Cambridge, MA, USA.
authors.forename: V A
authors.initials: VA
authors.lastname: Miller
authors.affiliation: Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: F
authors.initials: F
authors.lastname: Davies
authors.affiliation: Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: B
authors.initials: B
authors.lastname: Barlogie
authors.affiliation: Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
authors.forename: G
authors.initials: G
authors.lastname: Morgan
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D056742:Cyclin D2 / Q000235:genetics; D005500:Follow-Up Studies; D059014:High-Throughput Nucleotide Sequencing / Q000379:methods; D006801:Humans; D039641:Integrin beta Chains / Q000235:genetics; D048369:MAP Kinase Kinase 1 / Q000037:antagonists & inhibitors*; D020935:MAP Kinase Signaling System / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000627:therapeutic use*; D054389:Receptors, CCR1 / Q000235:genetics; D012189:Retrospective Studies
chemical_list: D014408:Biomarkers, Tumor; C080336:CCND2 protein, human; C515300:CCR1 protein, human; D056742:Cyclin D2; D039641:Integrin beta Chains; D047428:Protein Kinase Inhibitors; D011728:Pyridones; D011744:Pyrimidinones; D054389:Receptors, CCR1; C091368:integrin beta7; C560077:trametinib; D048369:MAP Kinase Kinase 1; C482125:MAP2K1 protein, human